Scholarlink

<p>Innate lymphoid cells (ILCs) are crucial for cancer immunosurveillance. While mouse&#xa0;type 1 ILCs (ILC1s) control acute myeloid leukemia (AML) by targeting leukemia stem cells (LSCs), the role of human ILC1s in AML remains largely undefined. Here, we find that ILC1s in AML patients are impaired, with reduced total ILC1 numbers and diminished function. In contrast, healthy donor (HD) ILC1s-derived TNFα inhibits the leukemic transition from CD34<sup>+</sup>CD38<sup>+</sup> to CD34<sup>−</sup>CD38<sup>+</sup> cells and blocks the differentiation of LSCs&#xa0;(CD34<sup>+</sup>CD38<sup>−</sup>) into immunosuppressive,&#xa0;macrophage-like leukemia-supporting cells. HD ILC1-derived IFNγ partially suppresses the differentiation of CD34<sup>−</sup>CD38<sup>+</sup> to CD34<sup>−</sup>CD38<sup>−</sup> cells. These combined effects limit human leukemogenesis in vivo. We also identify a human ILC1 subset as Lin<sup>−</sup>CD127<sup>+</sup>CD161<sup>−</sup>CRTH2<sup>−</sup>CD117<sup>−</sup> (CD161<sup><b>−</b></sup> ILC1s) that can be generated from umbilical cord blood CD34<sup>+</sup> hematopoietic stem cells. This method could provide a reliable source of ILC1s for potential adoptive transfer therapies in AML, offering a therapeutic approach to prolong disease-free survival in AML.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月5日

查看全文
  • Zhenlong Li,
  • Rui Ma,
  • Hejun Tang,
  • Ningyuan Liu,
  • Jianying Zhang,
  • Guido Marcucci,
  • Michael A. Caligiuri,
  • Jianhua Yu

摘要

Innate lymphoid cells (ILCs) are crucial for cancer immunosurveillance. While mouse type 1 ILCs (ILC1s) control acute myeloid leukemia (AML) by targeting leukemia stem cells (LSCs), the role of human ILC1s in AML remains largely undefined. Here, we find that ILC1s in AML patients are impaired, with reduced total ILC1 numbers and diminished function. In contrast, healthy donor (HD) ILC1s-derived TNFα inhibits the leukemic transition from CD34+CD38+ to CD34−CD38+ cells and blocks the differentiation of LSCs (CD34+CD38−) into immunosuppressive, macrophage-like leukemia-supporting cells. HD ILC1-derived IFNγ partially suppresses the differentiation of CD34−CD38+ to CD34−CD38− cells. These combined effects limit human leukemogenesis in vivo. We also identify a human ILC1 subset as Lin−CD127+CD161−CRTH2−CD117− (CD161− ILC1s) that can be generated from umbilical cord blood CD34+ hematopoietic stem cells. This method could provide a reliable source of ILC1s for potential adoptive transfer therapies in AML, offering a therapeutic approach to prolong disease-free survival in AML.